<DOC>
	<DOC>NCT01401530</DOC>
	<brief_summary>The purpose of this Phase 1 study is to determine the maximum tolerated dose (MTD) through observation of dose limiting toxicity (DLT), which is in advance defined, in patients with peripheral or cutaneous T-cell lymphoma.</brief_summary>
	<brief_title>E7777 for the Treatment of Patients With Peripheral T-Cell Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, T-Cell</mesh_term>
	<mesh_term>Lymphoma, T-Cell, Peripheral</mesh_term>
	<mesh_term>Denileukin diftitox</mesh_term>
	<criteria>lnclusion Criteria: Male and female patients 20 to less than 80 years of age at the time of informed consent Patients histologically or cytologically diagnosed to have peripheral T cell lymphoma Patients with a history of chemotherapy (including PUVA and retinoid) that resulted in relapse, recurrence and treatment resistance (just for the administration of E7777 alone) Patients subject to CHOP therapy and without a history of prior treatment with anthracycline or anthraquinone anticancer drugs (just for the administration of E7777 in combination with CHOP therapy) Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1 No carryover of beneficial or adverse effects of the prior treatment that may affect the safety evaluation of the investigational drug (excluding Grade 1 neuropathy and alopecia) Brain metastasis with clinical symptoms which requires treatment Serious systemic infection requiring intensive treatment Serious complications or histories History of hypersensitivity to protein therapeutics Known to be positive for HIV antibody, HCV antibody, or HBs antigen History of malignancy other than peripheral Tcell lymphoma and less than five years have elapsed since the last remission Patients who have undergone allogeneic hematopoietic stem cell transplantation Patients with a relapse within 6 months after autologous hematopoietic stemcell transplantation</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Neoplasms</keyword>
	<keyword>Neoplasms by Histologic Type</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Non-Hodgkin</keyword>
	<keyword>T- Cell</keyword>
	<keyword>Lymphatic Diseases</keyword>
	<keyword>Lymphoproliferative Disorders</keyword>
	<keyword>lmmune System Diseases</keyword>
	<keyword>lmmunoproliferative Disorders</keyword>
</DOC>